Background. It is unknown whether iron supplementation in human immunodeficiency virus (HIV)-infected children living in regions with high infection pressure is safe or beneficial. A 2-arm, double-blind, randomized, controlled trial was conducted to examine the effects of iron supplementation on hemoglobin, HIV disease progression, and morbidity.
preschool-aged children are anemic [1] . In developing countries, an overlap often exists between anemia and human immunodeficiency virus (HIV) infection in areas where both conditions are prevalent. This is not surprising since anemia is an important complication of HIV infection and is associated with poor survival and reduced quality of life [2, 3] . Recent studies suggest that iron supplementation may be harmful to ironreplete children living in areas with a high prevalence of infections (including malaria) [4, 5] . This prompted the World Health Organization (WHO) to recommend targeted iron supplementation for children at risk for anemia and iron deficiency [6] . However, this strategy is impractical in resource-limited countries where simple, reliable, and affordable tests for the assessment of iron status are not routinely available; and ferritin findings may be difficult to interpret due to high prevalence of infections [7, 8] . It is not known whether giving iron to HIV-infected children is safe or beneficial, given their increased susceptibility to infections and the suppressive effects of HIV type 1 infection on bone marrow hematopoiesis, which may not readily respond to iron [9, 10] . Our aim was to determine the effect of iron supplementation on hemoglobin level, HIV disease progression, and morbidity among HIV-infected children with anemia.
METHODS

Participants
We conducted a 2-arm, double-blind, randomized, placebocontrolled trial of oral iron supplementation in HIV-infected children aged 6-59 months with moderate anemia (defined as a hemoglobin level of 7-9.9 g/dL) between January 2009 and August 2010 in southern Malawi, a region of moderate-tointense perennial malaria transmission. Eligible participants were recruited from Thyolo District and Zomba Central Hospitals. HIV-positive children identified by universal HIV counseling and testing within the hospital were screened for anemia using the Hemocue 301 analyzer (HemoCue AB, Angleholm, Sweden). Children were excluded from participation if (1) they had evidence of severe malnutrition (defined as weight-forheight score of <75% of the age-expected value [11] ), (2) they were already receiving micronutrient supplements/fortified diets, (3) they were enrolled in another study involving treatment with medicinal products at the time of recruitment, or (4) they had a gross congenital, cognitive, or neurodevelopmental anomaly. All children received routine cotrimoxazole prophylaxis, which is standard practice for HIV management in Malawi.
Children whose parents/guardians provided written, informed consent were randomly assigned to 2 arms: the first (ie, iron) arm received 3 mg/kg of elemental iron and multivitamins (1500 IU/ mL of vitamin A, 35 mg/mL of vitamin C, and 400 IU/mL of vitamin D) as once-daily concentrated drops for 3 months, and the second (ie, placebo) arm received multivitamins alone oncedaily for 3 months. Both medicinal products were identical in appearance. The primary end point was the incidence of all-cause sick visits. All participants were followed for 6 months.
Procedures
Recruitment
On enrollment, a blood sample was taken for complete blood count (ABX Micros 60, Horiba ABX S.A.S, Montpellier, France), malaria microscopy, blood cultures, and basic biochemistry assays, including measurement of C-reactive protein (CRP) and serum ferritin levels. Serum samples collected for ferritin and CRP assessment were stored at −80°C until study completion and then shipped to the Netherlands, where the assays were run as a fully automated single-in-one series, using the Beckman LX20 chemistry analyzer (Beckman Coulter, Brea, CA). In addition, urine and stool analyses were performed to exclude bacterial and parasitic infections. Positive results for infection were treated according to standard hospital protocols.
Follow-up
Study participants were seen 1, 2, 3, and 6 months after recruitment in the study clinic, at which time they were assessed for adherence to study medication, general well being, and nutritional status. At recruitment and the 1-and 2-month visits, guardians were given a month's supply of study medications. At each scheduled hospital visit, a blood and urine sample was collected for hemoglobin measurements, malaria microscopy (on clinical suspicion of malaria), and urine analysis. In addition, serum samples were collected at 3 and 6 months for measurement of CRP and ferritin levels. Children who presented to the hospital because of an illness before the scheduled hospital visits were examined and treated according to standard hospital protocols. Children who did not show up for the scheduled follow-up after a week were traced to their homes by research staff. Details of hospital sick visits by trial participants to other healthcare facilities before their scheduled hospital visit were collected from their health passport books and parent/guardian interviews at the time they presented for a routine follow-up or hospital sick visit.
Case Definitions
Malaria was defined by the presence of Plasmodium falciparum asexual parasites on Giemsa-stained thick blood smear microscopy, regardless of the presence of symptoms. The parasite density was documented as the number of parasites per 200 white blood cells in the thick smear [12] . Malaria slides were independently read by 2 readers, and if the initial results differed by >25% slides were read by a third reader.
A respiratory infection was defined as a history of cough or runny nose, along with fast breathing (respiratory rate, >50 breaths/minute if aged <1 year and >40 breaths/minute if aged >1 year) and signs of respiratory distress (ie, chest in-drawing, labored breathing, and grunting) [13] .
The number of children who progressed to AIDS in each arm was determined by using a combination of clinical [14] and immunological (CD4 percentage, <20%) criteria assessed for each trial participant at 3-and 6-month visits. Iron deficiency was defined as serum ferritin level of <30 µg/dL for subjects with a CRP level of ≥5.0 mg/L (evidence of inflammation) and as a serum ferritin level of <12 µg/dL for those with a CRP level of <5.0 mg/L [15, 16] .
Randomization and Blinding
Block randomization (random block sizes ranging from 2-8) with 1:1 allocation was used and stratified by study site. The blinded participant-specific study drugs were prepared in accordance with a computer-generated randomization list by a designated person who otherwise was not involved in the study. Study drugs were prepacked in sealed envelopes and labeled with the study numbers for each study site. A copy of the study code for each participant was kept in sealed envelopes by the trial safety monitor.
Ethical approval was obtained from the College of Medicine Research Ethics Committee (COMREC), Malawi. The clinical trial registration number was ISRCTN 62947977.
Sample Size Calculation and Statistical Analysis
A sample size of 1260 was initially calculated based on data from a large case-control study [17] , in which we assumed that the mean number (±SD) of sick-child clinic visits among HIVinfected children over 6 months of follow-up would be 2.2 ± 2.2 visits, with iron supplementation regarded as safe if the incidence of sick visits was not increased by >15%, compared with placebo, with 90% power to infer noninferiority, assuming 10% loss to follow-up. This calculation was made before the scale up of highly active antiretroviral therapy (HAART) in Malawi, and morbidity in HIV-infected children was high [18] . However, because of changes in national policy on HAART use in pregnant women and children, which took effect soon after study commencement [19] , it became clear that we needed to revisit our sample size calculation because our former projections were no longer valid. Thus, a new sample size of 240 children (120 per intervention arm) was calculated based on the change in hemoglobin level over 6 months follow-up, which gave 80% power and 95% confidence to detect a mean change in hemoglobin level of 1.1 gm/L between the 2 intervention arms, assuming 10% loss to follow-up. COMREC was duly informed of the changes. Recruitment was completed in February 2010; all participants were followed until August 2010.
Data were analyzed by intention to treat, using Stata 10 (StataCorp, College Station, TX). Multiple linear regression models were used to test the intervention effect on changes in hemoglobin level and CD4 percentage over the follow-up period, with treatment effects presented as the mean difference (MD). Prevalence end points were summarized as percentages, with treatment effects expressed as prevalence ratios (PRs), and as the number of events per 100 person-years, with the treatment effect expressed as incidence rate ratios (IRRs) for morbidity outcomes, using negative binomial regression. All prespecified treatment effects were adjusted for important baseline variables (ie, previous blood transfusion in the past 3 months, bed net use, HAART use, CD4 percentage at recruitment, and baseline hemoglobin level). These were selected after exploring the association between baseline variables and outcome variables in univariate models, and variables with a P value of < .10 were entered into the initial full multivariable model. Exploratory analyses were done to determine the extent that magnitude of treatment effects varied with time (active intervention vs passive postintervention period), age (<24 months or >24 months), baseline iron status (iron deficient vs iron replete), bed net use, and HAART use at recruitment, using interactionterm models [20] . Because the study lacked power to test for treatment-effect modification, we used the magnitude of the treatment-effect ratio between subgroups and its corresponding Abbreviation: HAART, highly active antiretroviral therapy. a Data are for 200 subjects (data were missing for 4 in the iron arm and 5 in the placebo arm).
b Data are for 195 subjects (data were missing for 9 in the iron arm and 5 in the placebo arm).
c Data are for 198 subjects (data were missing for 6 in the iron arm and 5 in the placebo arm).
d Defined as an axillary temperature of ≥37.5°C. g Defined as detection of asexual parasites on blood smear microscopy.
P value to guide our conclusions. For all other statistical analyses, P values of < .05 were taken as statistically significant, and each estimate is reported with a 95% confidence interval. All comparisons made between the 2 intervention arms were designed before the start of the study, and interaction terms were used for all treatment-effect modification analyses, thereby reducing the risk of type 1 errors.
RESULTS
A total of 209 HIV-infected children were recruited from 2 hospitals between January 2008 and February 2010. One-hundred and ninety-six patients (93.8%) completed 6 months follow-up ( Figure 1 ). Baseline characteristics of study participants are summarized in Table 1 . The mean age (±SD) was 25.8 ± 15.9 months and 47.4% (99/209) of the study population were male. The median hemoglobin level at baseline was 9.4 g/dL (interquartile range [IQR], 8.6-9.8 g/dL), and the prevalence of iron deficiency was 34.5% (72/209; Table 1) . Changes in hemoglobin level, CD4 percentage, the prevalence of anemia (defined as a hemoglobin level of <11 g/dL), and the prevalence of iron deficiency over the study follow-up period are summarized in Table 2 . Iron supplementation was associated with a better hemoglobin response, compared with placebo, at 3 months (adjusted mean difference [aMD], 0.62 g/ dL; 95% confidence interval [CI], .20-1.04; P = .004) and 6 months of follow-up (aMD, 0.60 g/dL; 95% CI, .06-1.13, P = .03). Iron supplementation was also associated with a reduced risk of anemia persisting at 3 months (adjusted PR [aPR], 0.71; 95% CI, .51-.97; P = .03) and 6 months (aPR, 0.59; 95% CI, .38-.92; P = .02) of follow-up. In addition, iron supplementation was associated with a reduced risk of iron deficiency (aPR, 0.28; 95% CI, .15-.49; P < .001), and a better CD4 percentage response at 3 months (aMD, 6.00; 95% CI, 1.84-10.16; P = .005) but not at 6 months of follow-up (P > .05).
Morbidity outcomes by intervention period are presented in Table 3 . Iron supplementation was associated with an increased risk of malaria over the 6-month follow-up period ( Treatment-effect modification of morbidity outcomes by age, iron status, bed net use, and HAART use are presented in Table 4 . Iron supplementation was associated with an increased risk of malaria in children >24 months old, compared with children <24 months old (IRR, 3.30; 95% CI, 1.28-8.49; P = .01; P interaction = .10), and in children who did not use bed nets (IRR, 4.12; 95% CI, 1.89-8.98; P ≤ .001; P interaction = .003). In addition, iron supplementation was associated with a reduced risk of progression to AIDS in iron-deficient children (IRR, 0.25; 95% CI, .08-.83; P = .02; P interaction = .07; Table 4 ).
DISCUSSION
To our knowledge, this is the first double-blind, randomized, placebo-controlled trial of iron supplementation for the treatment of anemia in HIV-infected children living in an area with a high pressure of infections (including malaria). We have tried to conduct our study to mirror common practice in resourcelimited settings, where iron supplements are routinely given for the treatment of anemia without prior determination of iron status. In this way, our study findings can be generalized for similar settings. Care was taken to ensure that all HIV-infected children in whom treatable causes of anemia (malaria and hookworm infestation) were found at recruitment received standard treatments in accordance with hospital policy.
Furthermore, we chose to give an active placebo (containing vitamins A, C, and D), rather than an inactive drug, based on an assumption that HIV-infected children in our study population may be deficient in multiple micronutrients. Thus, children randomly assigned to the placebo arm would also benefit from the administration of these additional vitamins (excluding iron) [17, 21] . Iron supplementation in our study cohort increased hemoglobin levels and reduced the prevalence of anemia persisting at 6 months of follow-up visit by 40%, but increased the risk of malaria by 6 months. Our study was unable to determine the true effect of iron supplementation on all-cause sick visits, allcause hospital admissions, and progression to AIDS by 6 months.
The improvement in hemoglobin levels following iron supplementation in our study cohort is in agreement with previous observational studies on iron supplementation in HIV-infected children conducted in Italy [22] and India [23] . It also demonstrates that iron deficiency plays an important role in the multifactorial etiology of anemia in HIV-infected children and should be addressed when considering treatment options for anemia in HIV-infected children living in resource-limited settings.
Iron supplementation in our study was also associated with a better CD4 percentage response at 3 months of follow-up. This observation is in line with the findings of a US-based study in a cohort of women with HIV and hepatitis C virus coinfection, following 6 months of iron supplementation [24] . Although we were unable to determine the exact mechanism for the beneficial effect of iron on cell-mediated immunity, it may have been due to the beneficial effects of iron on CD4 T-cell proliferation and function, which have been demonstrated in previous studies performed in iron-deficient children without HIV infection [25, 26] .
Iron supplementation appeared to increase the risk of malaria particularly during the active-intervention period but was protective against respiratory infections during the postintervention period, which are 2 contrasting effects. Perhaps the differential effects of iron on malaria and respiratory infections may be related to the mechanisms by which different pathogens derive iron from the body. While Plasmodium species make use of the labile intracellular iron pool, which can be significantly increased by iron supplementation, many bacteria derive iron either by the use of high-affinity siderophores or by direct interaction with circulating iron-transport protein complexes [27, 28] . The untoward association between iron supplementation and malaria morbidity has been highlighted in previous trials done in the Gambia, Papa New Guinea, and Tanzania [4, 5, 29, 30] . The increased risk for adverse outcomes with iron appears to be mostly limited to regions with a high prevalence of malaria, as a large trial of iron and folic acid supplementation in preschool-aged children performed in southern Nepal (an area with a low malaria risk) did not show significant differences in morbidity and mortality but appeared to be protective against acute respiratory infections [31] . The significant interaction between iron supplementation and age resulting in a higher incidence of malaria in children older than 24 months was an unexpected finding, as children aged 6-24 months are usually at a greater risk of severe disease and death following malaria because of an immature immune response [32] . This observation may be because younger children are more likely to be iron deficient owing to nutrient-poor weaning diets and, hence, to be protected from malaria (the baseline prevalence of iron deficiency among children aged <24 months was 48.7%, compared with 17.7% among children aged >24 months) [33, 34] . It is interesting to note that iron supplementation was associated with a slower progression to AIDS in iron-deficient children. The reason for this finding is unclear, but it may be related to the observed beneficial effect of iron on CD4 T-cell immunity seen at 3 months follow-up. It is clear that further studies are needed to elucidate the mechanisms by which iron supplementation resulted in its beneficial effects on immunity and HIV-disease progression in iron-deficient children.
The main limitation of our study was that we were unable to determine the true effect of iron supplementation on all-cause sick visits, hospitalizations, and progression to AIDS. However, the effect of iron on malaria was very pronounced and statistically significant despite the reduced sample size. Another limitation of the study was that we were unable to examine the effect of iron supplementation on mortality. Studies examining this outcome in HIV-infected children are needed, as studies in HIV-infected adults suggest that iron supplementation may be associated with an increased risk of mortality [35, 36] .
In conclusion, our findings suggest that iron supplementation in HIV-infected children has beneficial effects on hemoglobin level, anemia, and immune function but increases the risk of malaria. On the basis of these findings, one may consider combining interventions of iron supplementation with malaria protection in malaria-endemic regions. It is clear that further studies are needed to unravel the complex but interesting interaction between iron, immunity, and infections in HIVinfected children.
Notes
